A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-10-10
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 143); relationship: N
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-30 (study day 151); relationship: not assessed
moderate
assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-20 (study day 172); relationship: N
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-15 (study day 197); relationship: not assessed
Data queries
No data queries.